Breaking News Instant updates and real-time market news.

TEVA

Teva

$42.96

-1.32 (-2.98%)

, REGN

Regeneron

$371.68

-4.11 (-1.09%)

07:00
10/17/16
10/17
07:00
10/17/16
07:00

Teva, Regeneron say FDA places Phase 2b fasinumab study on clinical hold

TEVA

Teva

$42.96

-1.32 (-2.98%)

REGN

Regeneron

$371.68

-4.11 (-1.09%)

  • 30

    Oct

  • 04

    Nov

  • 06

    Nov

  • 15

    Nov

  • 29

    Mar

TEVA Teva
$42.96

-1.32 (-2.98%)

10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
REGN Regeneron
$371.68

-4.11 (-1.09%)

10/13/16
BTIG
10/13/16
NO CHANGE
Target $18
BTIG
Buy
Ocular deal with Regeneron has favorable terms, says BTIG
BTIG analyst Ling Wang believes Ocular Therapeutix's (OCUL) strategic collaboration with Regeneron (REGN) comes with favorable deal terms. The back-end loaded structure brings the potential for large upside, Wang tells investors in a research note. In addition, the partnership provides external validation for Ocular's platform technology, Wang adds. The analyst reiterates a Buy rating on the shares with an $18 price target
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.

TODAY'S FREE FLY STORIES

MO

Altria Group

$73.65

0.68 (0.93%)

08:00
02/22/17
02/22
08:00
02/22/17
08:00
Hot Stocks
Breaking Hot Stocks news story on Altria Group »

Altria Group reaffirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

VFC

VF Corp.

$52.42

-0.26 (-0.49%)

08:00
02/22/17
02/22
08:00
02/22/17
08:00
Upgrade
VF Corp. rating change  »

VF Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

, PLKI

Popeyes

$78.73

12.61 (19.07%)

07:56
02/22/17
02/22
07:56
02/22/17
07:56
Recommendations
Restaurant Brands, Popeyes analyst commentary  »

Restaurant Brands…

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

PLKI

Popeyes

$78.73

12.61 (19.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Mar

ARGS

Argos Therapeutics

$4.40

-0.3 (-6.38%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Hot Stocks
Breaking Hot Stocks news story on Argos Therapeutics »

Argos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Apr

GS

Goldman Sachs

$251.76

1.38 (0.55%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Initiation
Goldman Sachs initiated  »

Goldman Sachs initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

RDS.A

Royal Dutch Shell

$52.49

0.29 (0.56%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Conference/Events
Royal Dutch Shell to hold a conference call »

EVP of Gas and Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ACRX

AcelRx

$3.15

0.05 (1.61%)

, CBM

Cambrex

$54.90

0.55 (1.01%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Conference/Events
RBC Capital to hold a conference »

Global Healthcare…

ACRX

AcelRx

$3.15

0.05 (1.61%)

CBM

Cambrex

$54.90

0.55 (1.01%)

CRIS

Curis

$2.66

-0.02 (-0.75%)

ESPR

Esperion

$24.42

-0.58 (-2.32%)

DVAX

Dynavax

$3.95

-0.05 (-1.25%)

FLXN

Flexion

$19.66

0.43 (2.24%)

GILD

Gilead

$69.29

-0.56 (-0.80%)

CURE

Curative Health Services Inc

$33.80

0.45 (1.35%)

PCRX

Pacira

$44.15

0.45 (1.03%)

NVDQ

Novadaq

$6.76

0.17 (2.58%)

AXON

Axovant Sciences

$12.11

-0.03 (-0.25%)

TSRO

TESARO

$190.27

-0.09 (-0.05%)

EGRX

Eagle Pharmaceuticals

$73.59

-0.53 (-0.72%)

LPNT

LifePoint

$65.15

1.25 (1.96%)

PRTA

Prothena

$55.00

-0.22 (-0.40%)

ABEO

Abeona Therapeutics

$5.25

-0.75 (-12.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 02

    Mar

  • 06

    Mar

  • 17

    Mar

  • 21

    Mar

  • 01

    Apr

  • 27

    Apr

  • 30

    Jun

  • 06

    Oct

MS

Morgan Stanley

$46.56

0.41 (0.89%)

07:54
02/22/17
02/22
07:54
02/22/17
07:54
Initiation
Morgan Stanley initiated  »

Morgan Stanley initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:53
02/22/17
02/22
07:53
02/22/17
07:53
Conference/Events
Forecasters Club of New York to hold a luncheon meeting »

Federal Reserve Governor…

USPH

U.S. Physical Therapy

$76.10

2 (2.70%)

07:52
02/22/17
02/22
07:52
02/22/17
07:52
Conference/Events
CFA Society of Houston to hold a luncheon meeting »

Chris Reading, CEO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 21

    Mar

  • 29

    Mar

  • 11

    Apr

  • 12

    Apr

SOHO

Sotherly Hotels

$7.04

-0.4 (-5.38%)

07:51
02/22/17
02/22
07:51
02/22/17
07:51
Recommendations
Sotherly Hotels analyst commentary  »

Sotherly Hotels can still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$45.60

-0.02 (-0.04%)

07:49
02/22/17
02/22
07:49
02/22/17
07:49
Initiation
Glaukos initiated  »

Glaukos initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

DBD

Diebold

$29.70

-0.4 (-1.33%)

07:48
02/22/17
02/22
07:48
02/22/17
07:48
Initiation
Diebold initiated  »

Diebold initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FSLR

First Solar

$36.62

1.78 (5.11%)

07:45
02/22/17
02/22
07:45
02/22/17
07:45
Downgrade
First Solar rating change  »

First Solar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$126.34

1.07 (0.85%)

07:45
02/22/17
02/22
07:45
02/22/17
07:45
Hot Stocks
Aetna announces $3.3B accelerated share repurchase »

Aetna announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Conference/Events
CFA Society of Washington, D.C. to hold a luncheon discussion »

The CFA Society of…

CSCO

Cisco

$34.13

0.39 (1.16%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Recommendations
Cisco analyst commentary  »

Cisco at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 03

    Mar

M

Macy's

$32.29

-0.01 (-0.03%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Recommendations
Macy's analyst commentary  »

Macy's risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

NVIDIA

$111.07

3.84 (3.58%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Initiation
NVIDIA initiated  »

NVIDIA initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

EYEG

EyeGate

$3.70

2.0601 (125.62%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Syndicate
Breaking Syndicate news story on EyeGate »

EyeGate files $3.29M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCN

Welltower

$66.94

1.02 (1.55%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Hot Stocks
Welltower enters into strategic collaboration with Johns Hopkins Medicine »

Welltower announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 27

    Feb

  • 01

    Mar

HD

Home Depot

$145.02

2.02 (1.41%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Recommendations
Home Depot analyst commentary  »

Home Depot guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

AMD

AMD

$14.00

0.87 (6.63%)

07:41
02/22/17
02/22
07:41
02/22/17
07:41
Initiation
AMD initiated  »

AMD initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

, PLKI

Popeyes

$78.73

12.61 (19.07%)

07:41
02/22/17
02/22
07:41
02/22/17
07:41
Recommendations
Restaurant Brands, Popeyes analyst commentary  »

Oppenheimer sees…

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

PLKI

Popeyes

$78.73

12.61 (19.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Mar

SBGI

Sinclair Broadcast

$36.90

0.4 (1.10%)

07:40
02/22/17
02/22
07:40
02/22/17
07:40
Hot Stocks
Sinclair Broadcast sees FY17 barter and trade revenue $116M »

Consensus for FY17 total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.